Essex Bio-Technology Executes HKD 0.14 Million Share Buyback, Treasury Shares Reach 0.13% of Issued Capital

Bulletin Express06-26

Essex Bio-Technology Limited disclosed that on 26 June 2026 it repurchased 50,000 ordinary shares on the Hong Kong Stock Exchange at HKD 2.70 per share, for a total consideration of HKD 0.14 million.

Following the transaction, the company’s issued share capital (excluding treasury shares) fell to 566.28 million shares from 566.33 million, representing a marginal reduction of 0.0088%. Treasury shares increased to 723,000, lifting treasury holdings to approximately 0.13% of the total issued shares of 567.01 million.

The buyback was executed under the general mandate granted on 26 May 2026, which authorises Essex Bio-Technology to repurchase up to 56.70 million shares. Cumulative repurchases under this mandate now stand at 723,000 shares—about 1.28% of the authorised limit—leaving roughly 55.98 million shares available for future buybacks.

All shares acquired on 26 June 2026 were retained as treasury shares; none have been cancelled. In accordance with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 26 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182252591?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 17:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182252591","market":"us","top_or_hot":-1,"title":"Essex Bio-Technology Executes HKD 0.14 Million Share Buyback, Treasury Shares Reach 0.13% of Issued Capital","media":"Bulletin Express","content":"<p>Essex Bio-Technology Limited disclosed that on 26 June 2026 it repurchased 50,000 ordinary shares on the Hong Kong Stock Exchange at HKD 2.70 per share, for a total consideration of HKD 0.14 million.</p>\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) fell to 566.28 million shares from 566.33 million, representing a marginal reduction of 0.0088%. Treasury shares increased to 723,000, lifting treasury holdings to approximately 0.13% of the total issued shares of 567.01 million.</p>\n<p>The buyback was executed under the general mandate granted on 26 May 2026, which authorises Essex Bio-Technology to repurchase up to 56.70 million shares. Cumulative repurchases under this mandate now stand at 723,000 shares—about 1.28% of the authorised limit—leaving roughly 55.98 million shares available for future buybacks.</p>\n<p>All shares acquired on 26 June 2026 were retained as treasury shares; none have been cancelled. In accordance with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 26 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Essex Bio-Technology Executes HKD 0.14 Million Share Buyback, Treasury Shares Reach 0.13% of Issued Capital</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEssex Bio-Technology Executes HKD 0.14 Million Share Buyback, Treasury Shares Reach 0.13% of Issued Capital\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-26 17:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Essex Bio-Technology Limited disclosed that on 26 June 2026 it repurchased 50,000 ordinary shares on the Hong Kong Stock Exchange at HKD 2.70 per share, for a total consideration of HKD 0.14 million.</p>\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) fell to 566.28 million shares from 566.33 million, representing a marginal reduction of 0.0088%. Treasury shares increased to 723,000, lifting treasury holdings to approximately 0.13% of the total issued shares of 567.01 million.</p>\n<p>The buyback was executed under the general mandate granted on 26 May 2026, which authorises Essex Bio-Technology to repurchase up to 56.70 million shares. Cumulative repurchases under this mandate now stand at 723,000 shares—about 1.28% of the authorised limit—leaving roughly 55.98 million shares available for future buybacks.</p>\n<p>All shares acquired on 26 June 2026 were retained as treasury shares; none have been cancelled. In accordance with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 26 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01061","symbol_name":"亿胜生物科技","start_time":0,"source_url":"","article_id":"1182252591","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182252591","pubTimestamp":1782465925,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Essex Bio-Technology Limited disclosed that on 26 June 2026 it repurchased 50,000 ordinary shares on the Hong Kong Stock Exchange at HKD 2.70 per share, for a total consideration of HKD 0.14 million....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01061":"亿胜生物科技"},"translate_title":"亿胜生物科技执行14万港元股份回购，库存股达已发行股本0.13%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":1},"content_text":"Essex Bio-Technology Limited disclosed that on 26 June 2026 it repurchased 50,000 ordinary shares on the Hong Kong Stock Exchange at HKD 2.70 per share, for a total consideration of HKD 0.14 million.\nFollowing the transaction, the company’s issued share capital (excluding treasury shares) fell to 566.28 million shares from 566.33 million, representing a marginal reduction of 0.0088%. Treasury shares increased to 723,000, lifting treasury holdings to approximately 0.13% of the total issued shares of 567.01 million.\nThe buyback was executed under the general mandate granted on 26 May 2026, which authorises Essex Bio-Technology to repurchase up to 56.70 million shares. Cumulative repurchases under this mandate now stand at 723,000 shares—about 1.28% of the authorised limit—leaving roughly 55.98 million shares available for future buybacks.\nAll shares acquired on 26 June 2026 were retained as treasury shares; none have been cancelled. In accordance with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 26 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182252591","isCrawlerRequest":true}